TY - JOUR
T1 - Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma
T2 - An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
AU - Jain, Tania
AU - Bar, Merav
AU - Kansagra, Ankit J.
AU - Chong, Elise A.
AU - Hashmi, Shahrukh K.
AU - Neelapu, Sattva S.
AU - Byrne, Michael
AU - Jacoby, Elad
AU - Lazaryan, Aleksandr
AU - Jacobson, Caron A.
AU - Ansell, Stephen M.
AU - Awan, Farrukh T.
AU - Burns, Linda
AU - Bachanova, Veronika
AU - Bollard, Catherine M.
AU - Carpenter, Paul A.
AU - DiPersio, John F.
AU - Hamadani, Mehdi
AU - Heslop, Helen E.
AU - Hill, Joshua A.
AU - Komanduri, Krishna V.
AU - Kovitz, Craig A.
AU - Lazarus, Hillard M.
AU - Serrette, Justin M.
AU - Mohty, Mohamad
AU - Miklos, David
AU - Nagler, Arnon
AU - Pavletic, Steven Z.
AU - Savani, Bipin N.
AU - Schuster, Stephen J.
AU - Kharfan-Dabaja, Mohamed A.
AU - Perales, Miguel Angel
AU - Lin, Yi
N1 - Publisher Copyright:
© 2019 American Society for Transplantation and Cellular Therapy
PY - 2019/12
Y1 - 2019/12
N2 - Axicabtagene ciloleucel (YESCARTA; Kite Pharma, a Gilead Company, Los Angeles CA) and tisagenlecleucel (KYMRIAH; Novartis Pharmaceuticals Corp., Basel, Switzerland) are two CD19-directed chimeric antigen receptor (CAR) T cell products currently approved by the US Food and Drug Administration; the European Medicines Agency; Health Canada; Ministry of Health, Labor and Welfare (Japan); and Therapeutic Goods Administration (Australia) for treatment of specific subtypes of relapsed/refractory aggressive B cell non-Hodgkin lymphoma (NHL). Although this approval has been transformative in the use of cellular immunotherapy in lymphoma, there are concerns regarding appropriate use of this novel therapy and of short- and long-term toxicities. To address these issues, representatives of the American Society of Transplantation and Cellular Therapy convened to recognize and address key issues surrounding the clinical application of CD19 CAR T cell therapy in B cell lymphomas, in collaboration with worldwide experts. The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL. As the clinical practice using CAR T cells grows worldwide, we anticipate that this guidance will be relevant for hematology/oncology physicians who care for patients with lymphomas.
AB - Axicabtagene ciloleucel (YESCARTA; Kite Pharma, a Gilead Company, Los Angeles CA) and tisagenlecleucel (KYMRIAH; Novartis Pharmaceuticals Corp., Basel, Switzerland) are two CD19-directed chimeric antigen receptor (CAR) T cell products currently approved by the US Food and Drug Administration; the European Medicines Agency; Health Canada; Ministry of Health, Labor and Welfare (Japan); and Therapeutic Goods Administration (Australia) for treatment of specific subtypes of relapsed/refractory aggressive B cell non-Hodgkin lymphoma (NHL). Although this approval has been transformative in the use of cellular immunotherapy in lymphoma, there are concerns regarding appropriate use of this novel therapy and of short- and long-term toxicities. To address these issues, representatives of the American Society of Transplantation and Cellular Therapy convened to recognize and address key issues surrounding the clinical application of CD19 CAR T cell therapy in B cell lymphomas, in collaboration with worldwide experts. The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL. As the clinical practice using CAR T cells grows worldwide, we anticipate that this guidance will be relevant for hematology/oncology physicians who care for patients with lymphomas.
KW - Chimeric antigen receptor T cell therapy
KW - Diffuse large B cell lymphoma
KW - Non-Hodgkin lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85072519127&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2019.08.015
DO - 10.1016/j.bbmt.2019.08.015
M3 - Review article
C2 - 31446199
AN - SCOPUS:85072519127
SN - 1083-8791
VL - 25
SP - 2305
EP - 2321
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 12
ER -